Last updated: February 23, 2026
What is NDC 72266-0159?
NDC 72266-0159 refers to a specific pharmaceutical product registered with the FDA's National Drug Code system. It is identified as Ozempic (semaglutide) injection, 1 mg per dose. The drug is used for type 2 diabetes management and belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class.
Market Position and Demand Drivers
Market Overview
- Indication: Management of type 2 diabetes with significant weight loss benefits. Approved for additional indications such as weight management (Wegovy).
- Market Size: The global GLP-1 receptor agonist market was valued at approximately $9 billion in 2022.
- Growth Trends: CAGR projected at 12% through 2028, driven by increasing diabetes prevalence and expanding approval for obesity treatment.
Key Competitors
- Victoza (liraglutide): Dominant in the GLP-1 class with extensive market penetration.
- Trulicity (dulaglutide): Popular for weekly dosing.
- Wegovy (semaglutide): A higher-dose formulation for weight management with rapid adoption.
Adoption Factors
- Efficacy in glycemic control and weight loss.
- Patient compliance facilitated by weekly injections.
- Favorable safety profile over competitive options.
- Prescriber and payer acceptance influenced by clinical data and formulary placements.
Current Pricing Landscape
Historical Pricing Data
| Drug |
Formulation |
List Price (per dose) |
Average Selling Price (ASP) |
Reimbursement Rate |
| Ozempic (NDC 72266-0159) |
1 mg prefilled pen |
$850 |
$810 |
85% |
| Victoza |
1.2 mg or 1.8 mg prefilled pen |
$790 |
$750 |
83% |
| Trulicity |
0.75 mg/week |
$880 |
$835 |
85% |
| Wegovy |
2.4 mg weekly |
$1,350 |
$1,290 |
85% |
All prices represent approximate averages as of Q4 2022.
Reimbursement and Payer Dynamics
- Commercial insurers typically reimburse 80-85% of list prices.
- Medicare Part D coverage influences net prices, with negotiated discounts.
- Payers favor drugs with proven clinical superiority, influencing formulary inclusion and copay structures.
Market Penetration and Future Demand Forecasts
Projections
- The demand for semaglutide (Ozempic) for diabetes is expected to grow at a CAGR of approximately 10% through 2028.
- Inflation-adjusted price increases are limited to 3-5% annually in stabilized markets.
- Adoption of higher-dose formulations (e.g., Wegovy) for weight management expands market size, potentially adding 30% growth over five years.
Regulatory and Policy Factors
- Pending formulary negotiations could pressure prices.
- Expanded approvals for obesity and other metabolic conditions increase total addressable market.
- Potential biosimilar entries in the next 5-8 years could influence pricing strategies.
Price Projection Summary
| Year |
Expected List Price per Dose |
Market Share |
Estimated Market Size (USD) |
Notes |
| 2023 |
$850 |
100% |
$4.25 billion |
Current baseline |
| 2024 |
$880 |
90% |
$4.3 billion |
Slight increase |
| 2025 |
$915 |
85% |
$4.35 billion |
Market expansion |
| 2026 |
$950 |
80% |
$4.4 billion |
Competitive pressures |
| 2027 |
$985 |
75% |
$4.2 billion |
Biosimilar threat |
| 2028 |
$1,020 |
70% |
$4 billion |
Market stabilization |
Key Considerations
- Price increases will be constrained by payer negotiations and competitive dynamics.
- Market share may decline if biosimilars or generics enter the market.
- Higher utilization owing to expanded indications could offset some pricing pressures.
Key Takeaways
- NDC 72266-0159, Ozempic, has a significant market share driven by clinical efficacy and convenience.
- Current ASP per dose remains stable, with slight increases projected through 2028.
- Market growth relies on increasing prevalence of type 2 diabetes and obesity, along with new formulary arrangements.
- Price competition, biosimilar entry, and regulatory shifts will influence pricing trajectory.
- Manufacturers should monitor payer policies and competitive innovations for strategic adjustments.
FAQs
1. How likely are biosimilar entries to impact Ozempic pricing?
Biosimilar competition is expected within 5-8 years, which could reduce prices by approximately 15-25%. Early entry depends on patent litigation and regulatory pathways.
2. What factors could accelerate demand for Ozempic?
Expanded FDA approvals for weight management and new clinical data showing superior efficacy could increase prescription volumes.
3. How do payer reimbursement policies influence net prices?
Reimbursement rates of 80-85% and formulary positioning dictate net prices and can lead to discounts and tiered copayment structures.
4. Are there regional differences in price projections?
Yes, pricing varies globally; developing markets often see lower prices due to economic constraints and different regulatory environments.
5. What are the risks of declining prices?
Introduction of cheaper alternatives, patent challenges, or changes in treatment guidelines could lead to downward price adjustments.
References
[1] IQVIA. (2022). Global GLP-1 receptor agonist market analysis.
[2] FDA. (2022). Product labeling for Ozempic (semaglutide).
[3] CMS. (2022). Medicare Part D reimbursement policies.
[4] Evaluate Pharma. (2022). Biotechnology market forecasts.
[5] Pharma Intelligence. (2022). Biosimilar entry timelines and impact.
